AI's real value in healthcare isn't diagnosis—it's catching traps in contracts
Healthcare giants hide price increases through thousands of shell companies, but once you sign, AI can't save you—the only answer is to feed your contract to AI before signing and ask: where's the trap?
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
Health giants hide billions through thousands of shell companies
Cuban notes UnitedHealth operates 3,000-plus subsidiaries with ~$150 billion in annual internal transfers—comparable to the 14th-largest state economy in the US. He explains how giants simultaneously raise premiums and deductibles while steering patients to undisclosed affiliates they own, generating extra profit through this structure.
— Mark CubanLong contracts leave AI helpless after you sign
Cuban argues the problem isn't technology but the contracts themselves—a Dallas PBM agreement spans 1,335 pages, and no amount of human effort can extract every hidden trap. He stresses that once you sign, AI is nearly powerless; its true value lies in pre-signature review, preventing you from signing a bad deal in the first place.
— Mark CubanWidespread AI contract review could collapse the whole system
Cuban calculates that more than 155 million Americans get coverage through employer plans—over 60% of the country. If those employers used AI to review contracts before signing, asking where the traps are, the entire BUCA and PBM system would collapse from losing its information advantage, and healthcare costs would crater.
— Mark CubanShrinking drug manufacturing from warehouses to shipping containers
Cost Plus Drugs has already compressed what once required a football-field-sized manufacturing line into a truck-sized pod, swapping drug batches every 4 hours using AI and robotics. Each pod costs ~$20 million; government is the first customer. Cuban aims to move hundreds in two years, thousands in five—he jokes that selling $20 billion in pods annually would make even Musk nervous.
— Mark CubanPersonalized drug design will trend toward zero cost
As large language models improve, Cuban expects the cost to design personalized drugs based on your DNA—even over-the-counter medications like ibuprofen—will fall toward zero. He suggests labs bundle this into subscription services the way 23andMe offers DNA testing for under $99, letting marginal costs spread across the user base.
— Mark CubanAI makes medical patents harder to defend
Cuban raises an underexplored tension: if doctors and researchers use AI to generate new therapies, the ideal of free information collides with IP holders' real interests. He foresees closed licensing models where you pay per inference using someone's model—complicating access to the data needed for training and reasoning.
— Mark CubanReplace employee health premiums with personal savings accounts
If advising the president, Cuban would replace insurance with savings: employers deposit the equivalent of an ACA Silver-plan premium into individual accounts, banks extend credit, government guarantees coverage, and federal stop-loss kicks in above the limit. If you never claim, retirement brings the balance plus interest—yours to keep. Unlike today's premiums, which you pay forever without benefit and still must fight to use.
— Mark CubanOnly two kinds of companies will exist: good at AI and bankrupt
Closing, Cuban says companies split into two camps: those adept with AI and those going bankrupt. Most founders are stuck at the stage of not daring to talk to AI—like fearing Lotus 1-2-3 spreadsheets back in the day. Whoever gets comfortable first spots opportunities no one else sees yet, including the basement-bound solo founders Cuban says will become trillion-dollar builders.
— Mark CubanIn their own words · checked verbatim
So UnitedHealth, 3,000 plus subsidiaries, $150 billion in intercompany transfers annually. That would make them number 14 in GDP in the United States among states.
Mark Cuban11:19
The city of Dallas on their PBM contract, I haven't been able to see their ASO contract yet, 1,335 pages. There's no group of humans with enough coffee on the planet to be able to catch everything they try to squeeze by.
Mark Cuban15:34
I'm using a prompt that asks a single question. Where are they fucking me over and what should I do about it?
Mark Cuban19:49
if that 67% of the employers representing 67%, the 160 million plus Americans actually did one thing, one thing, ran their contracts through AI before they signed them and negotiated from that, the entire system for the big BUCAs and big PBMs and all their subsidiaries would collapse.
Mark Cuban21:53
If we're selling $20 billion worth of pods a year, watch out, Elon.
Mark Cuban26:00
there's no better time to be an entrepreneur than right now. There will be the trillionaire in the basement. There will be somebody who puts out their own agent swarm, but does it on an entrepreneurial basis.
Mark Cuban30:23
The cost of designing a drug personalized to you after reviewing your DNA and knowing everything that it knows will start approaching zero as the capabilities of models go up.
Mark Cuban36:41
there's going to be two types of companies. Those who are great at AI and those who have gone out of business.
Mark Cuban57:37
Figures
| UnitedHealth subsidiaries | 3,000+ | 11:19 |
| UnitedHealth annual internal transfers | ~$150 billion | 11:19 |
| Cost Plus Drugs launch | 111 generic drugs, Jan 19, 2022 | 4:06 |
| Cost Plus Drugs current SKUs | ~4,000 | 4:06 |
| Participating pharmacies | 17,000 | 4:06 |
| Cost Plus Drugs markup | fixed 15% | 23:58 |
| Dallas PBM contract pages | 1,335 | 15:34 |
| Per-pod manufacturing cost | ~$20 million | 7:13 |
| Americans unable to pay $400 emergency bill | 40% | 32:29 |
Glossary
- ASO (Administrative Services Only)
- Intermediary within large insurers that manages medical claims for self-insured employers, often with opaque terms.
- PBM (Pharmacy Benefit Manager)
- Middleman negotiating with drugmakers on behalf of employers and insurers, managing prescription drug benefits.
- BUCA
- Collective term for the largest national health insurers in the US.
- ANDA (Abbreviated New Drug Application)
- FDA filing required for generic drugs to launch, assessed and charged separately for each drug.
- N of one
- A therapy or drug formulated for a single patient based on their individual characteristics.
- Stop loss
- Reinsurance self-insured employers buy to cap losses from catastrophic individual claims.
How to listen
HR and CFOs managing self-insured employee health plans, healthcare founders, investors asking which part of traditional industries AI actually fixes.
The middle section on Epic, the EHR vendor, adds little—skip it.